Chief Operating Officer · Spero Therapeutics, Inc. (SPRO)

Timothy Keutzer

A named executive officer of Spero Therapeutics in every fiscal year CompBrief holds from FY2022 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,438,569

Salary $456,167Stock awards $499,999Bonus $297,500

FY2022: $1,585,037

4th of 4 named executive officers at Spero Therapeutics by FY2023 total.

4 named officers on file for Spero Therapeutics, FY2023

Timothy Keutzer’s pay file — $29

  • 2 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Spero Therapeutics’s whole pay program stands against its peers

  • Spero Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SPRO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 16, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Timothy Keutzer’s full pay file as a PDF — free

More than this page: up to 10 years of Timothy’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Timothy Keutzer compensation by year

Spero Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Spero Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023
Salary$423,750$456,167
Bonus$148,750$297,500
Stock awards$424,997$499,999
Option awards$424,807$0
Non-equity incentive$153,000$174,420
Pension and deferred compensation$0$0
All other$9,733$10,483
Total$1,585,037$1,438,569

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Spero Therapeutics, Inc. DEF 14A filed April 16, 2024, accession 0001193125-24-097749, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Spero Therapeutics, Inc. filed document, accession 0001193125-24-097749. Every figure is read from that document and cited to the page and table it appears in. Filed April 16, 2024.

$1.6M
$1.4M
FY22
FY23
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Insider transactions since the last proxy

12 Form 4 lines since the FY2023 proxy (filed April 16, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-02-06Sale—18,652$2.36742,506
2026-02-04Sale—3,471$2.24761,158
2026-02-03Sale—24,224$2.14764,629
2026-02-02Grant or award derivative—137,000$0.00137,000
2026-02-02Grant or award—68,000$0.00807,744
2026-02-02Sale—18,891$2.20788,853
2025-08-28Sale—1,695$1.97739,744
2025-02-05Sale—3,974$0.78794,002

The 8 most recent of 12 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Spero Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Ankit MahadeviaFormer President and Chief Executive Officer (6)$2,385,905
Satyavrat ShuklaPresident and Chief Executive Officer$2,024,647
Tamara JosephFormer Chief Legal Officer (7)$1,455,126
Timothy Keutzer · this pageChief Operating Officer$1,438,569

The full Spero Therapeutics compensation record

free company brief

This page is one person within Spero Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Spero Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Timothy Keutzer's compensation dossier · One-time report. No refunds.